Hematologic Malignancy
Chronic Leukemia
CI-CAN-00000764Explore in graph →
Hematologic411 active trials10 approved drugs59 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000764Explore in graph →
Clinical trials
1,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06071624 | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | suspended | Phase 1 | 30 | Huda SalmanOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | suspended | Phase 2 | 20 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05377827 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies |
| suspended |
| Phase 1 |
| 6 |
| Washington University School of MedicineOTHER |
| 1 |
| Jul 21, 2026 |
| clinicaltrials |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | suspended | Phase 1 | 12 | David WaldOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06630221 | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | suspended | Phase 2 | 25 | Abhay Singh, MD MPHOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06662227 | Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors | suspended | Early Phase 1 | 30 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice(REVEAL) | suspended | — | 272 | AbbVieINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | suspended | Phase 2 | 120 | Shanghai Zhangjiang Biotechnology Limited CompanyINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | suspended | Phase 1 | 36 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials